ACR 20

ACR 20American College of Rheumatology 20% improvement response criteria (rheumatoid arthritis)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
At week 12, placebo-adjusted ACR 20, 50, and 70 response rates for secukinumab (150 mg or 300 mg) and for etanercept were similar in the principal analysis (Figure 2 and Table 2).
But he was more impressed by the week 12 ACR 20 responses in patients who had previously failed on three or more biologics: 71% with upadacitinib at 15 mg and 50% at 30 mg, compared with 23% in controls.
These data follow initial results that showed 58% of patients treated with Tremfya achieved an ACR 20 response at week 24, the primary endpoint of the study, compared with 18.4% of patients receiving placebo (p
In Palace-1, 38 per cent of patients treated with Otezla 30 mg twice daily achieved an ACR 20 response at week 16 versus 19 per cent of patients on placebo.
The primary outcome was ACR 20, which was consistently greater at each time point for MTX plus leflunomide compared with MTX monotherapy.
The group receiving TwHF extract had double the results of the sulfasalazine group with 65% compared with 32.8% achieving a 20% improvement in ACR 20 criteria.
By the end of the first week, 36% of twice-daily patients had an ACR 20 response, compared with 23% in the once-daily R788 group and 14% in the placebo group (P less than .001 for the twice-daily group and P = .04 for the once-daily group, compared with placebo).
Of 28 patients treated with this interleukin 1 receptor antagonist after failing a TNF blocker, only 8% achieved an ACR 20 response, and no patients achieved an ACR 50 or ACR 70 response, she said.
Overall, 50% of those on Enbrel had at least a 20% improvement in the American College of Rheumatology response criteria (ACR 20) at 6 months vs.
"I think that now, after 10 years, we finally came up with what will be the equivalent" of the American College of Rheumatology 20% improvement (ACR 20) in core-set measures of rheumatoid arthritis (Arthritis Res Ther.
Failure to achieve minor responses (for example, ACR 20 and Simplified Disease Activity Index [SDAI] 50%) at the 3-month mark had the potential to almost rule out successfully reaching the target at 6 months, the investigators wrote (Ann Rheum Dis.